Press releases
- Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
- Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
- Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
- Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
- Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
- Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
- Natera Reports First Quarter 2024 Financial Results
- New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
- Natera to Report its First Quarter 2024 Results on May 9
More ▼
Key statistics
As of last trade Natera Inc (45E:BER) traded at 96.50, -8.96% below its 52-week high of 106.00, set on Jun 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 96.50 |
---|---|
High | 96.50 |
Low | 96.50 |
Bid | 96.50 |
Offer | 97.00 |
Previous close | 92.00 |
Average volume | 129.00 |
---|---|
Shares outstanding | 122.80m |
Free float | 117.63m |
P/E (TTM) | -- |
Market cap | 13.55bn USD |
EPS (TTM) | -3.13 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 07:03 BST.
More ▼